ProMis Neurosciences, Inc.
1920 Yonge Street
92 articles with ProMis Neurosciences, Inc.
The debacle raised three broad questions: What will Biogen do next? Is the amyloid theory of Alzheimer’s now dead? And what else is going on in the Alzheimer’s drug development arena?
Aducanumab Failure: Selectivity for the Toxic Oligomer is Essential to Treating Root Cause of Alzheimer's Disease
Discontinued aducanumab phase 3 studies emphasize urgent need for therapies that target the toxic oligomer with exacting precision
ProMIS Neurosciences to Present Data for Potential Best-in-Class Antibody Candidates for Parkinson's Disease at AD/PD 2019 Conference
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, will present data for new antibody candidates that show stringent selectivity for the toxic forms of alpha-synuclein, considered a root cause of Parkinson's disease
ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, announced its operational and financial results for the year ended December 31, 2018.
Former Sanofi U.S. Chairman to provide guidance and assistance to ProMIS business development strategies and partnering plans
Discontinued crenezumab phase 3 studies underscore urgent need for therapies that target the toxic oligomer with extraordinary precision
Company to showcase its innovative Alzheimer's, Parkinson's and ALS programs
ProMIS Neurosciences to Present at Sachs Associates Neuroscience Innovation Forum and China Focus@JPMWeek
ProMIS to showcase its Alzheimer's, Parkinson's and ALS programs at notable biotech investor events
ProMIS Neurosciences Appoints Renowned Neuroscientist, Dr. Rudolph Tanzi, to Scientific Advisory Board
Dr. Rudolph Tanzi is a neuroscientist and geneticist with scientific expertise in Alzheimer's disease and brain health.
Development of therapeutic antibodies for Alzheimer's disease, Parkinson's disease and ALS are top priorities for drug development and potential partnering
ProMIS Neurosciences, Inc. today announced its operational and financial results for the three and nine months ended September 30, 2018.
ProMIS Neurosciences Discusses Critical Importance of Selectively Targeting the Root Cause of Alzheimer's Disease
Narrated white paper reveals lessons learned from 15 years of drug development; pressing need to selectively target the toxic oligomer.
ProMIS Neurosciences Identifies Novel Targets on Tau Protein Involved in the Development of Alzheimer's Disease and Other Dementias
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced the identification of novel targets on misfolded, pathological forms of tau.
Unique discovery platform generates new antibody candidates that block a root cause of Parkinson's Disease
The conference is being held on September 19-20, 2018 at the Vancouver Convention Centre East in Vancouver, British Columbia.
Dr. Kupiec to leverage neurodegenerative experience from prior senior positions at Pfizer and Sanofi-Synthelabo
ProMIS Neurosciences, Inc. today announced it has issued a narrated overview of second quarter 2018 operational results.
ProMIS Neurosciences, Inc. announced that it will be featured as a presenting company at the 20th Annual Rodman & Renshaw Global Investment Conference
ProMIS Neurosciences Oligomer Selective Antibody Therapeutic for Alzheimer's Disease, PMN310, Shows Potential for Improved Safety Profile in Direct Comparison to Other Amyloid Beta-Directed Antibodies in Clinical Development
Lack of PMN310 binding to amyloid deposits in Alzheimer's brain tissue may eliminate dose-limiting brain swelling seen with BAN2401 and aducanumab
The net loss for the three months ended June 30, 2018 was $2,214,861, compared to a net loss of $1,903,396 for the three months ended June 30, 2017.